EP Patent

EP3808345A1 — Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Assigned to Sanofi Mature IP · Expires 2021-04-21 · 5y expired

What this patent protects

Provided herein are methods of using cabazitaxel in mCRPC patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent.

USPTO Abstract

Provided herein are methods of using cabazitaxel in mCRPC patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent.

Drugs covered by this patent

Patent Metadata

Patent number
EP3808345A1
Jurisdiction
EP
Classification
—
Expires
2021-04-21
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi Mature IP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.